Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment cap SEATTLE, Sept. 29, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that its Board of Directors has approved a plan to issue one contingent value right ("CVR") for each share of Atossa common stock to enable shareholders to share in a portion of any proceeds received from the monetization of Atossa's first qualifying rare pediatric disease priority review voucher.
